This page shows the latest Ariad Pharma news and features for those working in and with pharma, biotech and healthcare.
of bolt-on acquisitions and licensing deals, including the $5.2bn takeover of cancer company Ariad Pharma.
ALK-inhibitor will treat NSCLC patients as second-line therapy. Takeda took a chance a few weeks ago when it acquired Ariad with lead pipeline prospect Alunbrig still under regulatory review ... Takeda agreed to buy Ariad earlier this year in a $5.2bn
Ariad has filed for approval in the US for brigatinib - its second drug - after positive results in lung cancer were reported at the ASCO conference. ... On Friday, the company announced it had licensed Latin American distribution rights to Pint Pharma
Comes after leukaemia drug passes EMA safety review. US pharma company Ariad Pharmaceuticals has licensed its cancer drug Iclusig to Italy-based firm Angelini Pharma to market in 23 Eastern European ... Angelini will handle all sales and marketing
As such, Ariad's job cuts only affect the US, with European roles unaffected. ... Following the reduction, Ariad will be left with 295 employees covering both regions.
Shares fall after leukaemia patients develop blood clots. . Investors continued to bail out of Ariad Pharmaceuticals after it was forced to terminate a pivotal trial of its leukaemia drug Iclusig because ... on the market (albeit with more restrictive
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Paris Panayiotopoulos joins the US biotech from EMD Serono. Paris Panayiotopoulos has moved from EMD Serono to join Ariad as its new president and CEO. ... Panayiotopoulos said: “I am very pleased to be joining ARIAD at this exciting time.
Effective from December 31 or upon finding of successor. Ariad Pharmaceuticals founder Harvey J. ... Marty Duvall, executive VP and chief commercial officer at Ariad, added: “Harvey enthusiastically embraced the evolution of ARIAD into a global
Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib). ... Ariad also announced that another director is due to join the board, bringing the total number of board members to 10.
Will lead launch of chronic myeloid leukaemia treatment Iclusig. Ariad Pharmaceuticals has appointed Bristol-Myers Squibb's (BMS) Jonathan Dickinson as general manager of its European business. ... He joins at an important time for Ariad in Europe as it
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Inspired by a recent Agnitio roundtable discussion with Allergan, Ariad Pharmaceuticals, Astellas and Ipsen Pharma. As the number of our digital channels and tools continually expand, there are many opportunities to
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...